OBJECTIVE： To provide evidence for rational use and clinical monitoring of Alprostadil lipid-micro injection （Lipo-PGE1）. METHODS： Adult inpatients receiving Lipo-PGE1 from hospital information system （HIS） of 159 hospitals were selected as research subject. Based on frequency statistics， population， clinical diagnosis， and average daily dose of Lipo-PGE1 were all studied. RESULTS： A total of 71 687 adult inpatients were included， and the male was more than female， mostly aged 61-75. The hospitalization duration was 8-14 d （45.01％）， most of patients were recovered （68.20％）. Lipo-PGE1 was wildly used in the clinic， and was used for 871 kinds of clinical diseases in total； top 3 diseases were cerebral infarction （9.06％）， non-insulin dependent diabetes mellitus （8.65％） and chronic ischemic heart disease （8.08％）. The average daily dose of different diseases and different hospitals were significantly different， mostly≤12.5 μg. CONCLUSIONS： As adjuvant drug， medical institutions and related supervision departments should formulate reasonable monitoring index and strengthen medication guidance and evaluation of Lipo-PGE1.